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1. Introduction 
The thyroglobulin (Tg) is a normal secretory product of the thyroid gland. Tg is stored in the 
follicular light of the thyroid where it constitutes the majority of colloid proteins. It is the 
place of synthesis and storage of thyroid hormones. 
This glycoprotein of high molecular weight (660 kDa) is constituted by two identical sub-
units bound by disulphide-bridges. Each sub-unit contains 2 749 amino acids (Malthiery & 
Lissitzky, 1987 and Van de Graf et al., 1997). Its gene is situated on the chromosome 8 and 
different isoforms of Tg are secreted by alternative splicing. This molecule is heterogeneous 
by its degree of iodination (0.2 to 1.0%), of glycosylation, and by its contents in oses and in 
sialic acid (8 to 10%). The epitopic map of Tg revealed approximately about forty antigenic 
determinants, twelve epitopes grouped together in six domains (Piechaczyck et al., 1985). 
The central region of the Tg molecule is in majority immunoreactive (Henry et al, 1990). 
Tg is not confined in the follicle, some molecules are co-secreted with thyroid hormones by a 
complex process which can modify it. Any conformational change entails a different 
antigenicity because some epitopes can be masked or on the contrary be exposed. Molecular 
forms of Tg found in the serum of patients with differentiated thyroid cancer correspond to 
dimeric Tg. It is little iodized and presents a change of the glycosylation (Sinadinovic et al., 
1992 and Druetta et al., 1998). The heterogeneousness of Tg in the thyroid gland is increased 
in the cancer (Persani et al., 1998) and the changes of its conformation modifies its 
immunoreactivity (Kohno et al., 1985). All these structural characteristics are very important 
to know and can give some explanations about differences between Tg assays. It is not 
surprising to notice differences between Tg assays which use monoclonal antibodies by 
definition very specific. The follow-up of the differentiated thyroid cancers is the essential 
indication of the dosage of the serum Tg. Tg signs the presence of normal or pathological 
thyroid tissue. It is not possible to differentiate the normal tissue of the cancerous tissue 
thanks to serum Tg value. One reference point is mentioned in the laboratory medicine 
practice guidelines (Baloch et al., 2003): one gram of normal thyroid releases about 1µg/L Tg 
into the circulation when the serum thyroid stimulating hormone (TSH) is normal and 0.5 
µg/L if the TSH value is suppressed below 0.1 mUI/L. Since its concentration is correlated 
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with the size rather than with the nature of nodule of the thyroid gland, Tg is not used for 
the diagnosis of the thyroid cancer. Routine preoperative measurement of serum Tg for 
initial evaluation of thyroid nodules is not recommended (Cooper et al., 2006). 
2. Thyroglobulin assay in serum  
Serum Tg measurement is a technically challenging assay for a marker of choice during 
the follow-up of differentiated thyroid cancer. The use of the Tg assays requires a good 
knowledge of the technical difficulties. The quality of current Tg assay methods varies 
and influences the clinical utility of this test. All techniques are today immunometric 
assays with isotopic signal or not. Several methodological problems must be taken into 
account: standardization, functional sensitivity, precision, hook effects, interference by 
heterophile antibodies and interference by Tg antibodies (TgAb) (Spencer et al., 1996). 
Precision and hook effects are two parameters which are usual in biology when markers 
are used in the follow-up of cancer. Every laboratory scientist knows that it is sometimes 
better to measure stored serum samples from the patient in the same run as the current 
specimen to better appreciate the variability of the marker during the time. As regards the 
hook effect it is careful either to use a technique in 2 steps or to dilute systematically the 
serum suspected of very high values of Tg. Heterophile antibodies may cause falsely 
elevated serum Tg levels as in al immunometric assays. It is possible to reduce this 
interference by using heterophile blocking tubes when these antibodies are suspected 
(Preissner et al., 2003). Even if some solutions were studied for the other problems 
(standardisation, functional sensitivity and interference by TgAb) all persist always for 
more than fifteen years and guidelines have been published (Baloch et al., 2003; Pacini et 
al., 2006; Borson-Chazot et al., 2008). 
2.1 Standardisation 
Different guidelines and consensus (Baloch et al., 2003; Pacini et al., 2006; Borson-Chazot et 
al., 2008) recommended the use of the European human reference material CRM 457 (Feldt-
Rasmussen U et al., 1996). Even if the use of this standard doesn’t resolve all problems 
between different techniques it will be a minimal consensus that manufacturers would 
follow to get a homogenous basis of standardisation. The CRM 457 is produced from normal 
thyroid tissue. Now we know that tissular Tg is not strictly the one which circulates in the 
blood (Schulz et al., 1989). The ideal standard would be a preparation of thyroglobulin 
extracted from the blood. Because of a too small quantity of circulating Tg the 
manufacturing of such a reference was not possible. The actual recommendation is to use 1:1 
CRM 457 standardisation. The configuration of the Tg molecule is not enough taken into 
account in the various Tg methods. 
2.2 Functional sensitivity 
Since Tg measurements have to detect very small amount of thyroid tissue, it is absolutely 
necessary to determine the sensitivity of the Tg assays. The definition of the functional 
sensitivity was established by Spencer for the TSH (Spencer et al., 1996 a). The same concept 
can be applied to Tg (Spencer et al, 1996 b): it is the Tg value that can be measured with 20% 
between-run coefficient of variation (CV), using a 1:1 CRM 457 standardisation. The 
proposed protocol is similar for Tg with the establishment of a profile of precision 
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measuring human pool sera over 6 to 12 months (compatible deadline with the follow-up of 
the patients) with at least 2 batchs of reagents and 2 instrument calibrations (Baloch et al., 
2003). The pools of serum used for this profile have to be TgAb negative. It must be repeated 
to the scientists how to verify the functional sensitivity of a Tg assay and not to take that 
given by the manufacturer. Analogous to TSH, Tg assay functional sensitivity permits a 
generational classification of Tg assays. Most current assays are actually first generation 
with a functional sensitivity about 0.5 to 1.0µg/L. The functional sensitivity is of a big 
importance to determine the «detectable Tg < institutional cut-off » mentioned in the 
European Consensus (Pacini et al., 2006) specially in the flow chart for the follow-up after 
initial treatment (6 to 12 months) and recombinant human thyrotropin (rhTSH). For example 
some authors (Kloos & Mazzaferri, 2005) considered a thyroglobulin cutoff level of 2.0µg/L 
highly sensitive for identifying persistent tumor after rhTSH stimulation in patients who 
had TSH-suppressed thyroglobulin undetectable with an assay functional sensitivity value 
of 1µg/L. This cut-off is also mentioned in the recommendations of the American Thyroid 
Association (Cooper et al., 2006). 
In the European consensus, supersensitive Tg assays which have a higher sensitivity but at 
the expense of a much lower specificity are not currently recommended for routine use. 
Nevertheless some current assays are second generation with a ten-fold better functional 
sensitivity. An insufficient functional sensitivity is at the origin of most of false-negative 
results corresponding to an authentic recurrence of the disease with a value of Tg given 
undetectable. With a more sensitive second generation assay it would be possible to detect 
responses that will be undetectable with a first generation assay. At present this very low 
functional sensitivity for certain cases of dosages could allow to replace rhTSH stimulated 
Tg testing for the patients at low risk by a simple dosage of second generation Tg. Low risk 
patients are those with well-differentiated papillary or follicular thyroid cancer, patient age 
<45 years, thyroid tumor size ranging from 1 cm to <4 cm in diameter, no extension of the 
tumor beyond the thyroid capsule, no lymph-node involvement and no distant metastases 
(Schlumberger et al., 2007; Smallridge et al., 2007; Schlumberger et al., 2011). 
2.3 Interference by TgAb 
This type of analytical problem is completely characteristic of Tg assays and exists in no 
other immunoassay. It is connected to the fact that Tg is a major auto-antigen. All the 
actually methods are prone to interference by TgAb (Mariotti et al., 1995). The combined 
use of judiciously selected monoclonal antibodies directed against antigenic domains of 
Tg not recognized by most TgAb allowed to develop a Tg assay with minimal interference 
from TgAb (Marquet et al., 1996). In every case the presence of TgAb that mask certain 
epitopes can lead to underestimation of the Tg concentrations with the actuals 
immunometric methods.  
We are however unable to evaluate the true interference of these TgAb:  it is known that 
in some patients few Tgab can induce a major interference while in some others a lot of 
TgAb induce only a smooth interference. Everything depends on the affinity of these 
antibodies which we do not estimate. The various consensus recommend to measure 
antibodies by a enough sensitive method in a systematic way with any dosage of Tg. At 
first it had been suggested realizing a test of recovery to estimate the importance of the 
interference but this one was abandoned because of a bad standardization of the protocol 
www.intechopen.com
 Thyroid and Parathyroid Diseases – New Insights into Some Old and Some New Issues 
 
26
(Spencer et al, 1996c). When there is presence of TgAb and if Tg is found undetectable, its 
value is not interpretable. When the value of Tg is dosable with presence of antibodies, 
the returned value is then a "minimal" value knowing that she could be more raised in the 
absence of antibody. After thyroidectomy, TgAb will decrease and disappear in patients 
with remission but these antibodies may persist during 2-3 years after disappearance of 
Tg (Chiovato et al., 2003). During the follow-up of some patients persistence or 
reappearance of circulating TgAb may be regarded as an indicator of disease. More 
recently Spencer even concluded that TgAb trends can be used as a surrogate tumor 
marker in differentiated thyroid cancer in preference to Tg measurement, provided that 
the same method is used. 
3. Thyroglobulin in fine needle aspiration biopsy 
After surgery for differentiated thyroid cancer, cervical ultrasound is recommended to 
evaluate the thyroid bed and central and lateral cervical nodal compartments should be 
performed at 6 and 12 months and then annually for at least 3-5 years, depending on the 
patients’ risk for recurrent disease and thyroglobulin status (Cooper et al., 2006). At present 
numerous studies describe the utility to look for thyroglobulin measurements in fine-needle 
aspiration biopsies (FNA-Tg) of lymph node (LN) during the follow-up of differentiated 
thyroid carcinoma. Although most patients have a long term survival rate, 5 to 20% of them 
will develop recurrence during follow-up, primarily in the cervical lymph nodes. An 
accurate distinction between metastatic and reactive benign lymph nodes (BLN) is essential 
in the management of thyroid cancer prior to surgery; it is necessary to specify the extent of 
surgery and identify early cervical relapse.  
Cytological examination of fine-needle aspiration cytology (FNA-C) the reference method 
for the diagnosis of thyroid nodules has also been, until recently, the best method to 
diagnose a cervical LN in subjects with suspicion of thyroid cancer or patients followed for 
thyroid neoplasia. However, sensitivity of FNA-C is far from excellent, varying from 75 to 
85% and altered by a high rate of non-diagnostic samples. Pacini was the first author who 
showed in 1992 high concentrations of thyroglobulin in metastatic LN of thyroid carcinoma. 
Although the performance of FNA-Tg is now well established, some methodological factors 
may influence the results and threshold value remains controversial. The first step is how to 
obtain the material from the fine needle aspiration. Ultrasound-guided fine-needle 
aspiration biopsy is carried out by a trained operator with a fine needle, preferably 25 to 27 
gauges. After aspiration, the needle is rinsed.  
3.1 The middle 
The middle used to rinse the needle is variable according to the teams; it can be either 
physiological saline solution or a liquid supplied by the laboratory (assay buffer or Tg-free 
serum). Two studies show that some parasite effects are present in the dosage: some “noise” 
in the Tg assay was described by Baskin et al. (2004). Snozek et al. (2007) demonstrate with a 
recovery test (after an overload of exogenous Tg) that the values of Tg are 25% higher with 
the saline solution than with a serous matrix with his Tg assay. The nature of the buffer may 
have an influence on the conformation of proteins and affect antibody binding. The most 
important matrix effect is that due to the matrix used to prepare the calibration curve and 
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the matrix to measure samples (Wild, 2005). We think that it is much better to use the Tg-
free medium of the test kit to avoid bias in the determination of thyroglobulin in FNA wash 
samples (Bournaud et al., 2010). But for practical use the saline solution is often used and so 
it is recommended in the French good practice guide for cervical ultrasound scan and echo-
guided techniques (Leenhardt et al., 2011) to check for the absence of matrix effect in the 
usual assay method. It is possible to validate the use of saline solution by comparing the 
results of Tg immunoreactivity obtained with Tg-free solution, saline solution and saline 
solution supplemented with serum albumin (Borel et al., 2008). 
3.2 The volume 
The quantity of the liquid used to rinse the needle varies between 0.5 to 1.0mL but is in 
general 1.0mL. All content of the needle is carefully removed by washing with from one to 
three pumping depending of the operator. Borel et al. (2008) shows that a triple pumping 
action of the 1 mL liquid through the needle was sufficient to wash out 97% of Tg out of the 
needle. If the needle has to be inserted several times into the same lymph node, the needle 
rinse can be poured into the same tube (Leenhardt et al., 2011). 
3.3 The Tg method 
The Tg method is the same used for the Tg serum assay. The problem of the interference 
by TgAb is however different. The presence of TgAb in fine needle aspiration biopsy 
washout can result of blood contamination when they are present or of active lymph node 
synthesis (Boi et al., 2006). But this interference seams to have small effect on the result of 
FNA-Tg. An explanation of this could be that the excessive high concentration of Tg is 
able to saturate TgAb binding sites. So it is not recommended to assay TgAb in the rinsing 
liquid (Leenhardt et al., 2011). 
Another interference could be also evoked: the contamination with serum Tg. It seems that 
FNA-Tg is not affected by the circulating serum levels. In 2008 Borel et al calculate that the 
maximal contamination of FNA-Tg by serum Tg varied from 0.003 to 0.012% what is not 
significant. He measured also albumin in the LN washout to evaluate the contamination by 
plasma proteins. He concluded that serum Tg did not interfere in results of FNA-Tg and 
specially in negative controls (not thyroidectomized) who had undetectable FNA-Tg values.  
3.4 The results and interpretation 
The expression of the results varies according to studies. Some authors (Baskin, 2004; Boi et 
al, 2006; Kim et al, 2009) use the unit µg/L (or ng/ml), others (Pacini et al., 1992; Cignarelli 
et al., 2003; Borel et al., 2008; Bournaud et al., 2010)  use µg/FNA. It is more suitable to use 
this type of result which reflects only the quantity of Tg present in the needle after rinsing 
and not a concentration of Tg in the LN.  
We find here again the problem of functional sensitivity of the Tg method which directly 
affect the cut-off value. In the first study (Pacini et al., 1992), the cut-off value was 21.7µg/L 
but the functional sensitivity was only 3µg/L. This cut-off value was established as equal to 
the mean plus two standard deviations of the FNA-Tg values in patients with negative 
cytology. Other authors used the same type of cut-off (Cignarelli et al., 2003; Baskin, 2004; 
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Boi et al., 2006). In other studies of the literature threshold are sometimes the functional 
sensitivity (Cunha et al., 2007; Snozek et al., 2007) or study of sensitivity and specificity and 
choice of the better cut-off with a Receiver Operating Characteristic Curve (ROC) (Bournaud 
et al., 2010; Giovanella et al., 2011). For others again the FNA-Tg is compared with serum 
Tg: when the FNA-Tg value is greater than serum Tg value the LN is considered as 
metastasis (Uruno et al., 2005; Sigstad et al., 2007). However there is no correlation between 
serous Tg and FNA-Tg (Frasoldati et al., 1999). Kim et al. (2009) tested different threshold 
and propose a combination: the threshold values for FNA-Tg levels should be >10ng/ml if 
the serum Tg level or the mean plus two standard deviation in node-negative patients is not 
available for reference. Finally the French consensus (Leenhardt et al., 2011) recommends: 
Tg <1ng/FNA: normal result, Tg between 1 and 10 ng/FNA: to be compared with the 
results from cytology and Tg> 10 ng/FNA: suggest the presence of tumoral tissue.  
FNA-Tg levels are significantly lower in subjects with metastatic poorly differentiated 
thyroid carcinoma than in subjects with differentiated thyroid cancer (Cignarelli et al., 2003) 
and may be nil (Boi et al., 2006), causing “false negatives” values.  
Conversely FNA-Tg is particularly usefull for the diagnosis of LN metastasis when these LN 
have cystic changes (Cignarelli et al., 2003; Baloch et al., 2008). FNA-Tg is more sensitive for 
detecting metastasis when compared with FNA cytology (FNA-C) alone and allows the 
accurate diagnosis for samples with non conclusive cytology (Giovanella et al., 2011). For 
patients who received therapy with 131I the delay between the treatment and FNA has to be 
enough long (more than 3 months) to allow definitive destruction of the metastatic LN 
because FNA-Tg value can be false-positive. Sensitivity of FNA-Tg in the different studies 
are comprise between 84% (Frasoldati et al., 1999) and 100% (Pacini et al., 1992; Snozek et al., 
2007; Cunha et al., 2007; Sigstad et al., 2007). When FNA-Tg is combined with FNA-C 100% 
sensitivity and 100% specificity can be obtained (Bournaud et al., 2010; Giovanella et al., 
2011). So FNA-C should remain combined with FNA-Tg (Leenhardt et al., 2011). 
4. Conclusion  
It seems that we can again progress in the evolution of the dosage of Tg in terms of quality. 
We underlined here the importance of analytical quality for a highly strategic parameter in 
the decision tree of the follow-up of differentiated thyroid cancer: the thyroglobulin. During 
these periods of great changes in laboratories with automation we have to remember 
ourselves another guideline: “choose a method Tg on the basis of its characteristics of 
performance not the costs”. The biologist has to know all the difficulties of Tg assays to 
argue the choice of his method, to guarantee the quality of the dosage and to avoid serious 
medical errors especially in the follow-up of differentiated thyroid carcinoma. A good 
laboratory-physician dialogue is more than ever of great importance. 
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